The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain - PubMed

The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain

A A Morrison et al. Biochem Cell Biol. 2006 Oct.

Abstract

Mutations in WT1 are associated with developmental syndromes that affect the urogenital system and neoplasms, including Wilms tumour, acute myeloid leukemia, and breast and prostate cancers. The WT1 protein belongs to the early growth response family of zinc-finger transcription factors. Uniquely to WT1, an evolutionarily conserved alternative splice event inserts the tripeptide KTS, between zinc fingers 3 and 4. Whereas -KTS isoforms bind DNA and activate or repress transcription, +KTS isoforms bind DNA less efficiently and interact with splice factors and RNA in vitro and in vivo. Although candidate DNA targets have been found, physiological mRNA targets are yet to be defined. We examined the distribution of WT1 in ribonucleoprotein (RNP) complexes in nuclear extract prepared from M15 cells, a mouse mesonephric fetal kidney cell line. WT1 cofractionated with the splice factor PSF in large RNP particles >or=2 MDa. We also found that PSF co-immunoprecipitated with WT1, suggesting a functional interaction between these 2 multifunctional proteins. Using yeast three-hybrid library constructed from the co-immunoprecipitated RNA we found that WT1 (+KTS) binds close to or at the start codon of alpha-actinin 1 (ACTN1) mRNA. A band shift assay confirmed the ability of the WT1 zinc-finger domain (+KTS) to bind this sequence in vitro. ACTN1 is the first likely physiological mRNA target of WT1.

Similar articles

• Expression in Xenopus oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one.

  Ladomery M, Sommerville J, Woolner S, Slight J, Hastie N. Ladomery M, et al. J Cell Sci. 2003 Apr 15;116(Pt 8):1539-49. doi: 10.1242/jcs.00324. J Cell Sci. 2003. PMID: 12640038

• The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.

  Han Y, San-Marina S, Yang L, Khoury H, Minden MD. Han Y, et al. Breast Cancer Res. 2007;9(4):R43. doi: 10.1186/bcr1743. Breast Cancer Res. 2007. PMID: 17634147 Free PMC article.

• Kinetic behaviour of WT 1's zinc finger domain in binding to the alpha-actinin-1 mRNA.

  Nurmemmedov E, Yengo RK, Ladomery MR, Thunnissen MM. Nurmemmedov E, et al. Arch Biochem Biophys. 2010 May;497(1-2):21-7. doi: 10.1016/j.abb.2010.02.013. Epub 2010 Mar 1. Arch Biochem Biophys. 2010. PMID: 20193655

• Wilms tumor and the WT1 gene.

  Lee SB, Haber DA. Lee SB, et al. Exp Cell Res. 2001 Mar 10;264(1):74-99. doi: 10.1006/excr.2000.5131. Exp Cell Res. 2001. PMID: 11237525 Review.

• DNA and RNA binding by the Wilms' tumour gene 1 (WT1) protein +KTS and -KTS isoforms-From initial observations to recent global genomic analyses.

  Ullmark T, Montano G, Gullberg U. Ullmark T, et al. Eur J Haematol. 2018 Mar;100(3):229-240. doi: 10.1111/ejh.13010. Epub 2018 Jan 10. Eur J Haematol. 2018. PMID: 29240258 Review.

Cited by

• The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes.

  Wells J, Rivera MN, Kim WJ, Starbuck K, Haber DA. Wells J, et al. Mol Cancer Res. 2010 Jul;8(7):975-85. doi: 10.1158/1541-7786.MCR-10-0033. Epub 2010 Jun 22. Mol Cancer Res. 2010. PMID: 20571064 Free PMC article.

• RNA Binding by the KTS Splice Variants of Wilms' Tumor Suppressor Protein WT1.

  Nishikawa T, Wojciak JM, Dyson HJ, Wright PE. Nishikawa T, et al. Biochemistry. 2020 Oct 13;59(40):3889-3901. doi: 10.1021/acs.biochem.0c00602. Epub 2020 Sep 29. Biochemistry. 2020. PMID: 32955251 Free PMC article.

• Wilms tumor protein-dependent transcription of VEGF receptor 2 and hypoxia regulate expression of the testis-promoting gene Sox9 in murine embryonic gonads.

  Kirschner KM, Sciesielski LK, Krueger K, Scholz H. Kirschner KM, et al. J Biol Chem. 2017 Dec 8;292(49):20281-20291. doi: 10.1074/jbc.M117.816751. Epub 2017 Oct 17. J Biol Chem. 2017. PMID: 29042436 Free PMC article.

• The podocyte as a target: cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutations.

  Stefanidis CJ, Querfeld U. Stefanidis CJ, et al. Eur J Pediatr. 2011 Nov;170(11):1377-83. doi: 10.1007/s00431-011-1397-6. Epub 2011 Feb 8. Eur J Pediatr. 2011. PMID: 21298518 Review.

• Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.

  Busch M, Schwindt H, Brandt A, Beier M, Görldt N, Romaniuk P, Toska E, Roberts S, Royer HD, Royer-Pokora B. Busch M, et al. Hum Mol Genet. 2014 Aug 1;23(15):3958-74. doi: 10.1093/hmg/ddu111. Epub 2014 Mar 11. Hum Mol Genet. 2014. PMID: 24619359 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ingenta plc
  • Ovid Technologies, Inc.

• Molecular Biology Databases

  • GlyGen glycoinformatics resource

• Miscellaneous

  • NCI CPTAC Assay Portal